Injections made from a gland in the brain of cattle. Long-running trials in older adults with heart disease reported fewer deaths, preserved physical capacity, fewer chest infections and lower blood pressure. Nearly all evidence comes from one group that also sells the preparation, side effects were never systematically collected, and no independent group has repeated the survival findings. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Night-time plasma melatonin | Above 50 pg/mL at 02:00–04:00 | Only measured predictor of response |
| Urinary 6-sulfatoxymelatonin | Above 20 µg per overnight collection | Non-invasive alternative to a night draw |
| Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) | Mid-reference for age and sex | Detects the bidirectional pituitary shift |
| Prolactin | 5–15 ng/mL | Third hormone shifting after injection |
| High-sensitivity C-reactive protein (hs-CRP) | Below 0.5 mg/L | Tracks the inflammatory background claimed to fall |
| Hemoglobin A1c (HbA1c) | 4.8–5.4% | The carbohydrate-metabolism claim |
| Fasting insulin | 2–5 µIU/mL | More sensitive than glucose to the claim |
| Apolipoprotein B (ApoB) | Below 80 mg/dL; below 60 at high risk | The particle count that predicts events |
| 24-hour ambulatory blood pressure | Daytime mean below 125/75 mmHg | The one validated surrogate moved |
| Leukocyte telomere length | No established target; track own baseline | The mechanism most often claimed |
Cadence: Melatonin and hormones 4 weeks after each course; metabolic and cardiovascular at 3 months; full set every 6–12 months